Fol. Biol. 2017, 63, 78-83
https://doi.org/10.14712/fb2017063020078
Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST)
Kacper Wasielewski1, B. Wasag
1,2, A. Wozniak
3, J. Pikiel
4, A. Kowalik
5, C. Osuch
6, E. Bylina
7, J. A. Siedlecki
8, P. Rutkowski
7, J. Limon
1,2
1Department of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland
2Laboratory of Clinical Genetics, University Clinical Centre, Gdansk, Poland
3Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals in Leuven, Leuven, Belgium
4Regional Oncology Centre, Gdansk, Poland
5Department of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland
6Department of General Surgery, Medical Faculty, Jagiellonian University, Krakow, Poland
7Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
8Department of Translational and Molecular Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
Received November 2016
Accepted January 2017
Crossref Cited-by Linking
- Chen Yan, Dong Xiuhua, Wang QiuJu, Liu ZhiXi, Dong XinWei, Shi Sanjun, Xiao HongTao: Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia. Front. Pharmacol. 2020, 11. <https://doi.org/10.3389/fphar.2020.569843>
